Peptide questions · Ecnoglutide
Ecnoglutide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for ecnoglutide are decreased appetite, diarrhea and nausea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: In the 40-week SLIMMER phase 3 trial in China, side effects of any kind were reported by 93% on ecnoglutide and 84% on placebo, mostly mild-to-moderate GI events; ten people on ecnoglutide stopped because of side effects.
What is commonly reported with ecnoglutide
- Decreased appetite
- Diarrhea
- Nausea
- Abdominal bloating
- Weakness
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Abdominal bloating | 1: Mazdutide |
| Weakness | None: listed for Ecnoglutide alone |

Model. Individual results vary.
Which ecnoglutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Ecnoglutide shares 4 of its 5 listed effects with at least one other metabolic & GLP-1 compound; weakness is listed for ecnoglutide alone.
What the ecnoglutide safety notes say
The library’s safety note
In the 40-week SLIMMER phase 3 trial in China, side effects of any kind were reported by 93% on ecnoglutide and 84% on placebo, mostly mild-to-moderate GI events; ten people on ecnoglutide stopped because of side effects. In the diabetes trials, GI side effects came mainly in the step-up period and faded, there was no severe low blood sugar, and pulse rose slightly, as with other GLP-1 drugs; a rise in the lab value lipase was more common than on placebo (about 12% vs 3%), worth knowing if a blood test shows it. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
In interaction studies in healthy people, ecnoglutide did not change warfarin or metformin enough to need a dose change, and its effects on rosuvastatin and digoxin were studied too. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the ecnoglutide reports come from
The library rates the evidence on ecnoglutide as established: clinical trials or FDA-approved use exist.
Of the library’s 8 research notes on ecnoglutide, 6 rest on randomized trials, 1 on clinical data and 1 on community reports.
Our 6 study pages on ecnoglutide: 5 randomized trials and 1 meta-analysis.
So ecnoglutide has controlled trials in people to set its listed effects against.
What our ecnoglutide study pages report on safety
Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis
Meta-analysis, human, 2026: Side effects were more common with ecnoglutide (risk ratio 1.09), mostly gut-related and mild to moderate, and serious side effects did not differ significantly between groups. In pooled trials of adults with type 2 diabetes, ecnoglutide lowered blood sugar and weight versus controls, with more side effects that were mostly mild gut symptoms and no significant rise in serious ones.
Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide
Randomized trial, human, 2025: Over 52 weeks, 3% of the 0.6 mg arm, 4% of the 1.2 mg arm, and 3% of the dulaglutide arm stopped treatment because of side effects.
Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg arm
Randomized trial, human, 2025: Side effects showed up in 93% of each ecnoglutide group and 84% of the placebo group, mostly mild-to-moderate stomach and gut problems, and some people on ecnoglutide stopped treatment because of them. In a large placebo-controlled trial, weekly ecnoglutide led to more weight loss at higher doses over 40 weeks, and most people had side effects, mainly mild-to-moderate stomach and gut problems.
Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trial
Randomized trial, human, 2023: In healthy people, weekly shots for up to 6 weeks were generally safe and well tolerated, with decreased appetite, nausea and headache among the side effects. The human part was an early-stage trial in healthy people lasting at most 6 weeks, and it measured safety and drug levels rather than weight loss or blood sugar control.
Questions people ask
What are the side effects of ecnoglutide?
The side effects most commonly reported for ecnoglutide are decreased appetite, diarrhea and nausea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Do ecnoglutide’s side effects come from human studies?
The library rates the evidence on ecnoglutide as established, and the library’s evidence on it includes controlled trials in people.
Which ecnoglutide side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists weakness for ecnoglutide alone.
Does ecnoglutide interact with other medicines?
The library’s interaction note on ecnoglutide begins: In interaction studies in healthy people, ecnoglutide did not change warfarin or metformin enough to need a dose change, and its effects on rosuvastatin and digoxin were studied too.